13 results about "Disease irritable bowel" patented technology

The invention belongs to the technical field of probiotics, and particularly relates to fermented lactobacillus mucus BM01 with an effect of relaxing bowel and application of the fermented lactobacillus mucus BM01. A new fermented lactobacillus mucus BM01 strain is separated from excrement of a healthy infant in Guangzhou city, Guangdong province, a zebra fish constipation model is constructed through loperamide hydrochloride, and research finds that the strain can remarkably promote intestinal tract movement, increase the content of in-vivo serotonin and inhibit the enzyme activity of dipeptidyl peptidase-4, so that the constipation of the zebra fish can be inhibited, the constipation of the zebra fish can be inhibited, and the constipation of the zebra fish can be inhibited. Therefore, the bowel relaxing effect is achieved. It is indicated that the BM01 strain can play the bowel relaxing effect through multiple mechanisms, has significant application value, can be used for research and development of drugs for treating constipation, irritable bowel syndrome and other intestinal diseases or development of health care products with the bowel relaxing effect, and can also be used as a feed additive to improve animal intestinal health and reduce disease risks. The culture benefit is improved.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

The invention provides a chemical entity of Formula (I):wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

This invention discloses a method for preparing an oral nanoparticle formulation of apigenin, belonging to the field of traditional Chinese medicine preparation technology. The method uses a mixture of soybean protein and xylan as the aqueous phase and an apigenin ethanol solution as the organic phase. Nanoparticles are prepared by antisolvent precipitation, followed by adsorption of tannic acid to obtain the final product. The nanoparticles prepared by this invention have a particle size of less than 600 nm and a high encapsulation efficiency. Utilizing the synergistic effect of soybean protein, xylan, and tannic acid, apigenin is protected from gastric acid degradation, achieving targeted intestinal delivery and significantly improving its oral bioavailability. This method can be used to prepare drugs for treating intestinal diseases such as inflammatory bowel disease, irritable bowel syndrome, or colorectal cancer.

This document relates to methods and materials involved in treating a mammal having a gastrointestinal disorder (e.g., an irritable bowel syndrome (IBS) such as post-infection IBS (PI-IBS)). For example, one or more protease inhibitors and / or one or more microorganisms that produce one or more protease inhibitors can be administered to a mammal having, or at risk of developing, a gastrointestinal disorder to treat the mammal.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

In some embodiments, the present disclosure relates to a non-transitory computer-readable medium storing computer-executable instructions that, when executed, cause a processor to perform operations, including forming an imaging dataset having imaging data corresponding to one or more radiological images of a patient having a bowel disease; operating upon the imaging data with one or more convolutional neural network (CNN) segments configured to generate a plurality of CNN outputs, the one or more CNN segments respectively including a convolution layer configured to perform a convolution on the imaging data; and applying a wavelet network to the plurality of CNN outputs to generate a plurality of convolution wavelet network (CWN) outputs, the wavelet network being configured to decompose the plurality of CNN outputs according to a mother wavelet. A predictive signature associated with disease response or risk is constructed using the plurality of CWN outputs.

Compositions comprising a mixture comprising the bacterial strain Bifidobacterium bifidum MIMBb23sg or BbfIBS01 (DSM 32708), at least one or more bacterial strains selected from group A comprising the strains B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BlIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) and, optionally, at least one further bacterial strain selected from a bacterial strain L. casei DG® (CNCM I-1572) and a bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, for example irritable bowel syndrome (IBS) are described.

The present invention discloses an EZH2 and HDAC dual-target inhibitor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, and a preparation method and use thereof. The cyclic amide structure in the general formula compound structure of the present invention is the key pharmacophore for inhibiting the activity of EZH2, and the hydroxamic acid moiety can effectively inhibit the activity of HDAC, thereby achieving dual inhibition of EZH2 and HDAC, having stronger activity. It can be used for preventing and / or treating diseases related to the dual targets of EZH2 and HDAC, especially tumors, cancers and inflammatory bowel diseases, such as lymphoma, sarcoma, melanoma, lung cancer, liver cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic cancer, thyroid cancer, laryngeal cancer, tongue cancer, head and neck cancer, multiple myeloma, B-cell lymphoma, leukemia, inflammatory bowel disease, and can play a synergistic role in the prevention and treatment of tumors, cancers and inflammatory bowel diseases.

Described herein are compositions and methods of treating gastrointestinal diseases and disorders such as irritable bowel syndrome and small intestinal bacterial overgrowth.

The present invention relates to a microbiome-based sitz bath method for patients with bowel disease. By periodically performing sitz baths for a certain period of time on mice induced with inflammatory bowel disease using sitz bath water containing an industrial lactic acid bacteria product as a microbial agent, it was confirmed that not only were symptoms of inflammatory bowel disease alleviated, but also the level of inflammatory cytokines was significantly reduced, compared to mouse groups orally or rectally administered with the lactic acid bacteria product. Accordingly, the present invention demonstrates that inflammatory bowel disease in the actual intestine is alleviated when a microbial agent such as a lactic acid bacteria product is included in sitz bath water for sitz bathing, and is thus provided as a microbiome-based sitz bath method for patients with bowel disease.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.